Phuong Nguyen

Phuong Nguyen

Auto-generated profile, based on publicly available information

Phuong Nguyen

St. Jude Children’s Research Hospital 1 Department of Bone Marrow Transplantation and Cellular Therapy Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LTLindsay J. Talbot
Lindsay J. Talbot
ACAshley Chabot
Ashley Chabot
ARAaron B. Ross
Aaron B. Ross
ABAlexandra Beckett
Alexandra Beckett
PNPhuong Nguyen
Phuong Nguyen
CDChristopher DeRenzo
Christopher DeRenzo
Purpose: Clinical efficacy of chimeric antigen receptor (CAR) T cells against pediatric osteosarcoma (OS) has been limited. One strategy to improve efficacy may be to drive chemokine-mediated homing of CAR T cells to tumors. We sought to determine the primary chemokines secreted by OS and evaluate the efficacy of B7-H3.CAR T cells expressing the cognate receptors. Experimental Design: We developed a pipeline to identify chemokines secreted by OS by correlating RNA-seq data with chemokine protein detected in media from fresh surgical specimens. We identified CXCR2 and CXCR6 as promising receptors for enhancing CAR T-cell homing against OS. We evaluated the homing kinetics and efficiency of CXCR2- and CXCR6.T cells and homing, cytokine production, and antitumor activity of CXCR2- and CXCR6.B7-H3.CAR T cells in vitro and in vivo. Results: T cells transgenically expressing CXCR2 or CXCR6 exhibited ligand-specific enhanced migration over T cells modified with nonfunctional control receptors. Differential homing kinetics were observed, with CXCR2.T-cell homing quickly and plateauing early, whereas CXCR6.T cells took longer to home but achieved a similar plateau. When expressed in B7-H3.CAR T cells, CXCR2- and CXCR6 modification conferred enhanced homing toward OS in vitro and in vivo. CXCR2- and CXCR6-B7-H3.CAR-treated mice experienced prolonged survival in a metastatic model compared with B7-H3.CAR T-cell-treated mice. Conclusions: Our patient-based pipeline identified targets for chemokine receptor modification of CAR T cells targeting OS. CXCR2 and CXCR6 expression enhanced the homing and anti-OS activity of B7-H3.CAR T cells. These findings support clinical evaluation of CXCR-modified CAR T cells to improve adoptive cell therapy for patients with OS.

2 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Purpose: Chimeric antigen receptor (CAR) T-cell therapy offers a promising approach to improve outcomes for patients with relapsed, refractory, or metastatic osteosarcoma. However, novel target antigens are needed to overcome obstacles limiting CAR T-cell efficacy against osteosarcoma and other solid tumors. Leucine-rich repeat-containing 15 (LRRC15) has been identified as a promising target in patients with osteosarcoma. Given these findings, we aimed to develop LRRC15-CAR T cells and evaluate their antitumor activity and safety in preclinical models. Experimental Design: We evaluated LRRC15 expression in normal tissues and pediatric solid tumors using gene expression and immunohistochemical (IHC) approaches. We generated LRRC15-CAR T cells using a binding domain that recognizes human and murine LRRC15 and evaluated their specificity, antitumor activity, and safety in preclinical studies. Results: Gene expression analysis demonstrated limited Lrrc15 expression in normal tissues and high expression in osteosarcoma, which was confirmed at the protein level by IHC staining of primary pediatric osteosarcoma tumors. In vitro, LRRC15-CAR T cells demonstrated specificity and cytotoxicity against LRRC15-positive targets. In vivo, LRRC15-CAR T cells exhibited antitumor activity in both human xenograft and immunocompetent murine osteosarcoma models, leading to significantly increased survival compared with controls. Finally, comprehensive toxicity analysis demonstrated a positive safety profile of intravenously administered LRRC15-CAR T cells. Conclusions: LRRC15-CAR T cells exert anti-osteosarcoma activity while maintaining a positive safety profile. These promising findings support the clinical translation of LRRC15-CAR T cells for patients with osteosarcoma and potentially other LRRC15-positive solid tumors.

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15 expression in human melanoma and melanocyte samples

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cell polyfunctionality after stimulation with LM7 osteosarcoma cells

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Tumors from mice with progressive intravenous LM7 lung osteosarcoma have limited LRRC15 expression after treatment with LRRC15-CAR T cells

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cells do not cause weight loss in tumor bearing mice